alcohol
High-Dose Baclofen for Treatment-Resistant Alcohol Dependence
Abstract: Alcohol dependence is associated with a wide array of physical and psychiatric complications and is a major cause of morbidity and mortality worldwide. Recent randomized trials of baclofen, with a total daily dose 30 mg administered in 3 divided doses, have supported its efficacy in reducing craving and promoting abstinence from alcohol. Individual case studies support a possible increased effect at higher doses for treatment-resistant patients.
The Anticonvulsant Levetiracetam Potentiates Alcohol Consumption in Non-Treatment Seeking Alcohol Abusers
Background: Levetiracetam (Keppra) is a commonly prescribed anticonvulsant that has been shown to attenuate alcohol consumption in an open-label study of treatment-seeking, alcohol-dependent subjects.
Methods: Here we performed a 42-day placebo-controlled, double-blind, randomized crossover trial to evaluate the effects of levetiracetam on moderate to heavy drinkers receiving either a low (500–1000 g/d) or a moderate (1000–2000 g/d) dose.